Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03347474
Other study ID # 2018-10-25 DBS-NAc Meth
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 20, 2017
Est. completion date December 30, 2020

Study information

Verified date October 2018
Source Ruijin Hospital
Contact Chencheng Zhang, MD
Phone +086-18217122884
Email i@cczhang.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main objective of this study is to assess the efficacy of bilateral deep brain stimulation (DBS) of the Nucleus Accumbens(NAc) as a novel treatment in severe methamphetamine addiction. Our hypothesis is that bilateral DBS of the NAc will significantly reduce the craving for methamphetamine.


Recruitment information / eligibility

Status Recruiting
Enrollment 10
Est. completion date December 30, 2020
Est. primary completion date September 20, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- DSM-IV-TR diagnosis of Drug addiction disorder;

- Age 18-65 years old;

- Proficiency in Mandarin language;

- Failure to detox more than three times;

- Capacity to provide informed consent (understanding of the study purpose and methods);

Exclusion Criteria:

- Multidrug abuse and formation of addiction;

- Serious and unstable organic diseases (e.g. unstable coronal heart disease);

- Any history of seizure disorder or hemorrhagic stroke;

- Past stereotactic neurosurgical intervention;

- Neurological disease (Abnormal PET-CT, MRI, EEG)

- Contraindications of MRI-examination, e.g. implanted cardiac pacemaker/ heart defibrillator;

- Contraindications of stereotactic intervention, e.g. increased bleeding disposition, cerebrovascular diseases (e.g. arteriovenous malfunction, aneurysms, systemic vascular diseases);

- HIV positive;

- Pregnancy and/or lactation;

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Bilateral surgical implantation of DBS system to NAc
The Medtronic, PINS and SceneRay DBS device will be utilized in the present study.

Locations

Country Name City State
China Shanghai Ruijin Hospital Functional Neurosurgery Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Ruijin Hospital

Country where clinical trial is conducted

China, 

References & Publications (1)

Kuhn J, Möller M, Treppmann JF, Bartsch C, Lenartz D, Gruendler TO, Maarouf M, Brosig A, Barnikol UB, Klosterkötter J, Sturm V. Deep brain stimulation of the nucleus accumbens and its usefulness in severe opioid addiction. Mol Psychiatry. 2014 Feb;19(2):145-6. doi: 10.1038/mp.2012.196. Epub 2013 Jan 22. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary change in 10-point visual analog scale of carving The score of scale is from 0 to 10. 0 represents no carving for drug, 10 means the greatest degree of carving for drug. Baseline (preoperative),3 months,6 months, 12 months
Primary change in Obsessive Compulsive Drug Use Scale Baseline (preoperative),3 months,6 months, 12 months
Secondary Side Effect Baseline(preoperative),3 months, 6 months, 12months
Secondary Change in the Hamilton Anxiety Scale Baseline(preoperative),3 months, 6 months, 12months
Secondary Change in the Hamilton Depression Scale Baseline(preoperative),3 months, 6 months, 12 months
Secondary Change in the Quality of Life Assessment (SF-36) Baseline(preoperative),3 months, 6 months, 12 months
Secondary Change in World Health Organization Quality of Life-BREF(WHO-BREF) Baseline(preoperative),3 months,6 months, 12 months
Secondary Chang in Pittsburgh Sleep Quality Index Baseline(preoperative),3 months,6 months, 12 months
Secondary Neuropsychological measures(Scores of cognitive battery) Baseline(preoperative),6 months,12 months
Secondary Change in Fagerstrom Test of Nicotine Dependence(FTND) Baseline(preoperative),3 months,6 months, 12 months